US20160136127A1 - Use of tetrahydrocannabinol and/or cannabidiol for increasing radiosensitvity in the treatment of a brain tumour - Google Patents
Use of tetrahydrocannabinol and/or cannabidiol for increasing radiosensitvity in the treatment of a brain tumour Download PDFInfo
- Publication number
- US20160136127A1 US20160136127A1 US14/899,598 US201414899598A US2016136127A1 US 20160136127 A1 US20160136127 A1 US 20160136127A1 US 201414899598 A US201414899598 A US 201414899598A US 2016136127 A1 US2016136127 A1 US 2016136127A1
- Authority
- US
- United States
- Prior art keywords
- cancer
- cells
- phytocannabinoids
- cbd
- thc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- CYQFCXCEBYINGO-IAGOWNOFSA-N [H][C@@]12C=C(C)CC[C@@]1([H])C(C)(C)OC1=C2C(O)=CC(CCCCC)=C1 Chemical compound [H][C@@]12C=C(C)CC[C@@]1([H])C(C)(C)OC1=C2C(O)=CC(CCCCC)=C1 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 2
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N [H][C@@]1(C2=C(O)C=C(CCCCC)C=C2O)C=C(C)CC[C@@]1([H])C(=C)C Chemical compound [H][C@@]1(C2=C(O)C=C(CCCCC)C=C2O)C=C(C)CC[C@@]1([H])C(=C)C QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Definitions
- the present invention relates to the use of phytocannabinoids for increasing radiosensitivity in the treatment of cancer.
- the phytocannabinoids used are either tetrahydrocannabinol (THC) and/or cannabidiol (CBD).
- Cancer is a disease in which a group of cells display the traits of uncontrolled growth. This means that the cells grow and divide beyond the levels of normal limits. The cells are also able to invade and destroy surrounding tissues. In addition cancer cells sometimes also metastasize, meaning that they spread to other locations in the body via the blood or lymph.
- cancers are caused by abnormalities in the genetic material of the cells. These abnormalities may be due to the effects of carcinogens. Other cancer-promoting genetic abnormalities may be randomly acquired through errors in DNA replication, or are inherited, and thus present in all cells from birth.
- Cancer-promoting oncogenes are often activated in cancer cells, giving those cells new properties, such as hyperactive growth and division, protection against programmed cell death, loss of respect for normal tissue boundaries, and the ability to become established in diverse tissue environments.
- Tumour suppressor genes are often inactivated in cancer cells, resulting in the loss of normal functions in those cells, such as accurate DNA replication, control over the cell cycle, orientation and adhesion within tissues, and interaction with protective cells of the immune system.
- cancer There are many different types of cancer and the cancer is usually classified according to the type of tissue from which it originated.
- Cancer is usually treated by one or more of the following: surgery, chemotherapy, radiation therapy, immunotherapy and monoclonal antibody therapy.
- the type of therapy depends upon the location and grade of the tumour and the stage of the disease.
- Cancers are known to affect many areas of the body with the most common types of cancers including: cancer of the bile duct, cancer of the bladder, cancer of the bone, cancer of the bowel (including cancer of the colon and cancer of the rectum), cancer of the brain, cancer of the breast, cancer of the neuroendocrine system (commonly known as a carcinoid), cancer of the cervix, cancer of the eye, cancer of the oesophagus, cancer of the head and neck (this group includes carcinomas that start in the cells that form the lining of the mouth, nose, throat, ear or the surface layer covering the tongue), Kaposi's sarcoma, cancer of the kidney, cancer of the larynx, leukaemia, cancer of the liver, cancer of the lung, cancer of the lymph nodes, Hodgkin's lymphoma, non-Hodgkin's lymphoma, melanoma, mesothelioma, myeloma, cancer of the ovary, cancer of
- a tumour that develops in the brain can destroy or damage brain cells by producing inflammation, compressing other parts of the brain, inducing cerebral oedema (brain swelling) and can cause increases in intracranial pressure (pressure within the skull).
- a primary brain tumour is a mass created by the growth or uncontrolled proliferation of cells in the brain. Malignant primary brain tumours are most likely to cause problems by spreading into the normal brain tissue which surrounds them and causing pressure and damage to the surrounding areas of the brain. These tumours rarely spread outside the brain to other parts of the body. However, secondary brain tumours occur when cancer cells from other parts of the body, such as the lung or breast spread to the brain.
- Surgery is the treatment option of choice for many brain tumours. Some may be completely excised, but those that are deep or that infiltrate brain tissue may be debulked rather than removed.
- Radiation therapy and/or chemotherapy may be recommended depending on the type of tumour involved.
- Glioma cell tumours can often be lethal.
- the characteristic diffuse infiltrative tumour growth of gliomas often makes the surgical removal of them impossible and this profoundly complicates the clinical management of these patients.
- Glioblastoma multiforme is the most common and most aggressive type of primary brain tumour and accounts for 52% of all primary brain tumour cases and 20% of all intracranial tumours.
- Phytocannabinoids are the active constituents of cannabis plants and they have been found to demonstrate numerous pharmacological properties.
- EP1177790 (Guzman et al.) describes the treatment of cerebral tumours by the administration of a natural or synthetic cannabinoid, specifically THC. It is claimed that activation of specific receptors leads to selective death of the transformed cells.
- gliomas are highly infiltrative and proliferative tumours, which follow a characteristic pattern of growth. Glioma cells invade the adjacent normal brain structures and surrounding large blood vessels.
- patent applications WO 2009/147439 and WO 2009/147438 respectively describe the use of a combination of the phytocannabinoids THC and CBD and the combination of the phytocannabinoids THC and CBD with chemotherapeutic agents in the treatment of glioma.
- phytocannabinoids tetrahydrocannabinol
- THC phytocannabinol
- CBD phytocannabidiol
- the brain tumour is a glioma tumour. More preferably the brain tumour is a glioblastoma multiforme (GBM).
- GBM glioblastoma multiforme
- the phytocannabinoids are in the form of an extract or botanical drug substance.
- the phytocannabinoids are in an isolated or pure form.
- the ratio of THC to CBD used may be in the range of from 99:1 to 1:99 (THC:CBD).
- THC:CBD is from 20:1 to 1:20 (THC:CBD). More preferably the ratio of THC:CBD is from 5:1 to 1:5 (THC:CBD). More preferably still the ratio of THC:CBD is substantially 1:1.
- “Cannabinoids” are a group of compounds including the endocannabinoids, the phytocannabinoids and those which are neither endocannabinoids nor phytocannabinoids, hereafter “syntho-cannabinoids”.
- Endocannabinoids are endogenous cannabinoids, which are high affinity ligands of CB1 and CB2 receptors.
- phytocannabinoids are cannabinoids that originate in nature and can be found in the cannabis plant.
- the phytocannabinoids can be present in an extract including a botanical drug substance, isolated, or reproduced synthetically.
- “Syntho-cannabinoids” are those compounds capable of interacting with the cannabinoid receptors (CB1 and/or CB2) but are not found endogenously or in the cannabis plant. Examples include WIN 55212 and SR141716 (rimonabant).
- An “isolated phytocannabinoid” is one which has been extracted from the cannabis plant and purified to such an extent that substantially all the additional components such as secondary and minor cannabinoids and the non-cannabinoid fraction have been removed.
- a “synthetic cannabinoid” is one which has been produced by chemical synthesis this term includes modifying an isolated phytocannabinoid, by for example forming a pharmaceutically acceptable salt thereof.
- a “botanical drug substance” or “BDS” is defined in the Guidance for Industry Botanical Drug Products Guidance, June 2004, US Department of Health and Human Services, Food and Drug Administration Centre for Drug Evaluation and Research as: “A drug derived from one or more plants, algae, or microscopic fungi. It is prepared from botanical raw materials by one or more of the following processes: pulverisation, decoction, expression, aqueous extraction, ethanolic extraction or other similar processes.”
- a botanical drug substance does not include a highly purified or chemically modified substance derived from natural sources.
- BDS derived from cannabis plants do not include highly purified Pharmacopoeial grade cannabinoids
- the structure of the phytocannabinoids, CBD and THC are as shown below:
- increase radiosensitivity refers to the ability of the phytocannabinoids to enhance the activity of irradiation provided during treatment for cancer.
- FIG. 1 shows the radiosensitivity of glioma cell lines
- FIG. 2 which shows the effect of CBD on the radiosensitivity of glioma cell lines
- FIG. 3 which shows the effect of THC on the radiosensitivity of glioma cell lines
- FIG. 4 which show the effect of combining THC and CBD on the radiosensitivity of glioma cell lines.
- the Example below describes the effect of using phytocannabinoids to increase radiosensitivity in glioma cells.
- the human glioma cell lines T98G and U87MG were obtained from ATCC, and were lines derived from patients with a glioblastoma multiforme tumour and a glioblastoma astrocytoma respectively.
- the mouse glioma cell line GL261, which is syngeneic to the C57BL/6 mouse was acquired from the NCI.
- Cells were initially seeded into flasks and left to adhere overnight. The following day they were irradiated with increasing doses of radiation (0, 1, 2, 5, 10 and 20 Gy) using Cs 137 as a radiation source. Cells were then harvested, counted and seeded again at increasing densities in 6-well plates, adjusting the density appropriately for the radiation dose, and then incubated for approximately 14 days. At this time, plates were washed and fixed in 70% ethanol, and colonies were stained with 5% methylene blue. Colonies consisting of >50 cells were counted and calculated as a proportion of the number of cells initially seeded (surviving fraction). This value is then used to calculate the radiosensitivity of the cell line. Data represents mean ⁇ SD of three independent experiments.
- Cells were initially seeded into flasks and left to adhere overnight. The following day they were treated with increasing concentrations of pure CBD and then left for 24 hours. Cells were then irradiated with increasing doses of radiation (0, 1, 2 and 5 Gy) using Cs 137 as a radiation source. Cells were then harvested, counted and seeded again at increasing densities in 6-well plates, adjusting the density appropriately for the radiation dose, and then incubated for approximately 14 days. At this time, plates were washed and fixed in 70% ethanol, and colonies were stained with 5% methylene blue. Colonies consisting of >50 cells were counted and surviving fraction was calculated. Data represents mean of three independent experiments except for GL261 which is only one data set.
- Cells were initially seeded into flasks and left to adhere overnight. The following day they were treated with increasing concentrations of pure THC and then left for 24 hours. Cells were then irradiated with increasing doses of radiation (0, 1, 2 and 5 Gy) using Cs 137 as a radiation source. Cells were then harvested, counted and seeded again at increasing densities in 6-well plates, adjusting the density appropriately for the radiation dose, and then incubated for approximately 14 days. At this time, plates were washed and fixed in 70% ethanol, and colonies were stained with 5% methylene blue. Colonies consisting of >50 cells were counted and surviving fraction was calculated. Data represents mean of three independent experiments.
- Cells were initially seeded into flasks and left to adhere overnight. The following day they were treated with increasing either pure THC, pure CBD or an equimolar 1:1 combination of both and then left for 24 hours. Cells were then irradiated with increasing doses of radiation (0, 1, 2 and 5 Gy) using Cs 137 as a radiation source. Cells were then harvested, counted and seeded again at increasing densities in 6-well plates, adjusting the density appropriately for the radiation dose, and then incubated for approximately 14 days. At this time, plates were washed and fixed in 70% ethanol, and colonies were stained with 5% methylene blue. Colonies consisting of >50 cells were counted and surviving fraction was calculated. Data from one data set only.
- FIG. 1 shows that the GL261 cell line is the most radiosensitive and that the human glioma cell lines were equally as sensitive.
- FIG. 2 shows the impact of CBD on radiosensitivity
- FIG. 3 shows data for the impact of THC on radiosensitivity. Results suggested that the phytocannabinoids, when used alone, did not appear to alter the radiosensitivity of the cell lines, as there is no dose dependent effect on the surviving fraction.
- FIG. 4 shows that a combination of THC and CBD at a final concentration of 20 ⁇ M may enhance the activity of irradiation, compared to using the agents alone.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB1310909.5 | 2013-06-19 | ||
GB1310909.5A GB2516814B (en) | 2013-06-19 | 2013-06-19 | Use of phytocannabinoids for increasing radiosensitivity in the treatment of cancer |
PCT/GB2014/051888 WO2014202989A1 (en) | 2013-06-19 | 2014-06-19 | Use of tetrahydrocannabinol and/or cannabidiol for increasing radiosensitivity in the treatment of a brain tumour |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2014/051888 A-371-Of-International WO2014202989A1 (en) | 2013-06-19 | 2014-06-19 | Use of tetrahydrocannabinol and/or cannabidiol for increasing radiosensitivity in the treatment of a brain tumour |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/969,422 Continuation US10758514B2 (en) | 2013-06-19 | 2018-05-02 | Use of tetrahydrocannabinol and/or cannabidiol for increasing radiosensitivity in the treatment of a brain tumour |
Publications (1)
Publication Number | Publication Date |
---|---|
US20160136127A1 true US20160136127A1 (en) | 2016-05-19 |
Family
ID=48914793
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/899,598 Abandoned US20160136127A1 (en) | 2013-06-19 | 2014-06-19 | Use of tetrahydrocannabinol and/or cannabidiol for increasing radiosensitvity in the treatment of a brain tumour |
US15/969,422 Active US10758514B2 (en) | 2013-06-19 | 2018-05-02 | Use of tetrahydrocannabinol and/or cannabidiol for increasing radiosensitivity in the treatment of a brain tumour |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/969,422 Active US10758514B2 (en) | 2013-06-19 | 2018-05-02 | Use of tetrahydrocannabinol and/or cannabidiol for increasing radiosensitivity in the treatment of a brain tumour |
Country Status (5)
Country | Link |
---|---|
US (2) | US20160136127A1 (es) |
EP (1) | EP3010497B1 (es) |
ES (1) | ES2732005T3 (es) |
GB (1) | GB2516814B (es) |
WO (1) | WO2014202989A1 (es) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10688191B2 (en) | 2018-01-19 | 2020-06-23 | Hr Biomed, Llc | Delivery of a chemotherapy agent across the blood-brain barrier |
US10758514B2 (en) | 2013-06-19 | 2020-09-01 | Gw Pharma Limited | Use of tetrahydrocannabinol and/or cannabidiol for increasing radiosensitivity in the treatment of a brain tumour |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2968929A1 (en) * | 2014-11-26 | 2016-06-02 | One World Cannabis Ltd | Synergistic use of cannabis for treating multiple myeloma |
GB2539472A (en) | 2015-06-17 | 2016-12-21 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
US10499584B2 (en) | 2016-05-27 | 2019-12-10 | New West Genetics | Industrial hemp Cannabis cultivars and seeds with stable cannabinoid profiles |
WO2019222459A1 (en) * | 2018-05-18 | 2019-11-21 | Diverse Biotech, Inc. | Cannabinoid preparations and therapeutic uses |
US12016829B2 (en) | 2019-10-11 | 2024-06-25 | Pike Therapeutics Inc. | Pharmaceutical composition and method for treating seizure disorders |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6566560B2 (en) | 1999-03-22 | 2003-05-20 | Immugen Pharmaceuticals, Inc. | Resorcinolic compounds |
US20040039048A1 (en) | 2000-02-11 | 2004-02-26 | Manuel Guzman Pastor | Therapy with cannabinoid compounds for the treatment of brain tumors |
ES1045342Y (es) | 2000-02-11 | 2001-02-16 | Alvarez Manuel Couto | Expositor giratorio para postales, fotos y similares. |
ES2164584A1 (es) * | 2000-02-11 | 2002-02-16 | Univ Madrid Complutense | Terapia con cannabinoides para el tratamiento de tumores cerebrales. |
US6448288B1 (en) | 2000-05-17 | 2002-09-10 | University Of Massachusetts | Cannabinoid drugs |
IL136839A (en) * | 2000-06-16 | 2006-12-10 | Yissum Res Dev Co | Pharmaceutical compositions comprising cannabidiol derivatives, and processes for the preparation of same |
US7429457B2 (en) | 2000-09-14 | 2008-09-30 | The Regents Of The University Of California | Id-1 and Id-2 genes and products as markers of epithelial cancer |
DE10051427C1 (de) | 2000-10-17 | 2002-06-13 | Adam Mueller | Verfahren zur Herstellung eines Tetrahydrocannabinol- und Cannabidiol-haltigen Extraktes aus Cannabis-Pflanzenmaterial sowie Cannabis-Extrakte |
GB2380129B (en) | 2001-02-14 | 2004-08-11 | Gw Pharma Ltd | Pharmaceutical formulations |
US6730330B2 (en) | 2001-02-14 | 2004-05-04 | Gw Pharma Limited | Pharmaceutical formulations |
US7025992B2 (en) | 2001-02-14 | 2006-04-11 | Gw Pharma Limited | Pharmaceutical formulations |
CH695661A5 (de) | 2001-03-06 | 2006-07-31 | Forsch Hiscia Ver Fuer Krebsfo | Pharmazeutische Zusammensetzung. |
GB0202385D0 (en) | 2002-02-01 | 2002-03-20 | Gw Pharma Ltd | Compositions for the treatment of nausea,vomiting,emesis,motion sicknes or like conditions |
US8034843B2 (en) | 2002-02-01 | 2011-10-11 | Gw Pharma Limited | Compositions comprising cannabinoids for treatment of nausea, vomiting, emesis, motion sickness or like conditions |
US20080057117A1 (en) | 2002-02-15 | 2008-03-06 | Forschungs Institut Miscia Verenfur Krebsforschung | Pharmaceutical composition made up of cannibus extracts |
IL148244A0 (en) | 2002-02-19 | 2002-09-12 | Yissum Res Dev Co | Anti-nausea and anti-vomiting activity of cannabidiol compounds |
US7285687B2 (en) | 2002-04-25 | 2007-10-23 | Virginia Commonwealth University | Cannabinoids |
US6946150B2 (en) | 2002-08-14 | 2005-09-20 | Gw Pharma Limited | Pharmaceutical formulation |
GB2391865B (en) | 2002-08-14 | 2005-06-01 | Gw Pharma Ltd | Improvements in the extraction of pharmaceutically active components from plant materials |
GB2394894B (en) | 2002-11-04 | 2005-08-31 | G W Pharma Ltd | New use for pharmaceutical composition |
GB2414933B (en) | 2004-06-08 | 2009-07-15 | Gw Pharma Ltd | Cannabinoid compositions for the treatment of disease and/or symptoms in arthritis |
GB2418612A (en) * | 2004-10-01 | 2006-04-05 | Gw Pharma Ltd | Inhibition of tumour cell migration with cannabinoids |
US7638558B2 (en) | 2005-04-01 | 2009-12-29 | Intezyne Technologies, Inc. | Polymeric micelles for drug delivery |
US7968594B2 (en) | 2005-04-27 | 2011-06-28 | Gw Pharma Limited | Pharmaceutical compositions for the treatment of pain |
CA2608399A1 (en) | 2005-05-13 | 2006-11-23 | Unimed Pharmaceuticals, Inc. | Dronabinol treatment of delayed chemotherapy-induced nausea and vomiting |
US8729133B2 (en) | 2006-02-28 | 2014-05-20 | Cornell University | Method for treating cancer |
GB2438682A (en) | 2006-06-01 | 2007-12-05 | Gw Pharma Ltd | New use for cannabinoids |
GB2439393B (en) | 2006-06-23 | 2011-05-11 | Gw Pharma Ltd | Cannabinoids for use in the treatment of neuropathic pain |
GB2448535A (en) | 2007-04-19 | 2008-10-22 | Gw Pharma Ltd | New use for cannabinoid-containing plant extracts |
US9084771B2 (en) | 2007-05-17 | 2015-07-21 | Sutter West Bay Hospitals | Methods and compositions for treating cancer |
GB2449691A (en) | 2007-05-31 | 2008-12-03 | Gw Pharma Ltd | A reference plant lacking medicinal active compound expression |
GB2460672B (en) * | 2008-06-04 | 2012-01-04 | Gw Pharma Ltd | Cannabinoids in combination with non-cannabinoid chemotherapeutic agents that are alkylating agents |
GB2471987B (en) | 2008-06-04 | 2012-02-22 | Gw Pharma Ltd | Anti-tumoural effects of cannabinoid combinations |
GB2478595B (en) | 2010-03-12 | 2018-04-04 | Gw Pharma Ltd | Phytocannabinoids in the treatment of glioma |
GB2516814B (en) | 2013-06-19 | 2016-08-31 | Otsuka Pharma Co Ltd | Use of phytocannabinoids for increasing radiosensitivity in the treatment of cancer |
-
2013
- 2013-06-19 GB GB1310909.5A patent/GB2516814B/en active Active
-
2014
- 2014-06-19 WO PCT/GB2014/051888 patent/WO2014202989A1/en active Application Filing
- 2014-06-19 EP EP14732613.6A patent/EP3010497B1/en active Active
- 2014-06-19 US US14/899,598 patent/US20160136127A1/en not_active Abandoned
- 2014-06-19 ES ES14732613T patent/ES2732005T3/es active Active
-
2018
- 2018-05-02 US US15/969,422 patent/US10758514B2/en active Active
Non-Patent Citations (2)
Title |
---|
Gilbert et al., Neuro Oncol. 2002;4(4):261-7. * |
Shrieve et al. International J. of Radiation Oncology*Biology*Physics, (1992), 24(4), p599-610. * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10758514B2 (en) | 2013-06-19 | 2020-09-01 | Gw Pharma Limited | Use of tetrahydrocannabinol and/or cannabidiol for increasing radiosensitivity in the treatment of a brain tumour |
US10688191B2 (en) | 2018-01-19 | 2020-06-23 | Hr Biomed, Llc | Delivery of a chemotherapy agent across the blood-brain barrier |
Also Published As
Publication number | Publication date |
---|---|
US10758514B2 (en) | 2020-09-01 |
EP3010497A1 (en) | 2016-04-27 |
GB2516814A (en) | 2015-02-11 |
EP3010497B1 (en) | 2019-04-10 |
GB201310909D0 (en) | 2013-07-31 |
GB2516814B (en) | 2016-08-31 |
US20190099398A1 (en) | 2019-04-04 |
WO2014202989A1 (en) | 2014-12-24 |
ES2732005T3 (es) | 2019-11-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10758514B2 (en) | Use of tetrahydrocannabinol and/or cannabidiol for increasing radiosensitivity in the treatment of a brain tumour | |
US20210069333A1 (en) | Cannabinoids in combination with non-cannabinoid chemotherapeutic agents | |
US20200138771A1 (en) | Anti-tumoural effects of cannabinoid combinations | |
ES2751340T3 (es) | Fitocannabinoides para su uso en el tratamiento del cáncer de mama | |
GB2478074A (en) | THC and CBD for use in the treatment of tumours | |
GB2478072A (en) | THC and CBD for use in the treatment of brain tumours |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: GW PHARMA LIMITED, UNITED KINGDOM Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LIU, WAI;SCOTT, KATHERINE;DALGLEISH, ANGUS;AND OTHERS;SIGNING DATES FROM 20161017 TO 20170209;REEL/FRAME:041746/0086 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |